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Abstract
To study the clinical correlates of the H63D mu-tation 
we have analysed the phenotype of H63D homo-
zygotes identified through mutation analysis in a referral 
laboratory. A total of 366 blood samples referred for 
HFE analysis were screened for C282Y and H63D 
mutations. Four H63D homozygotes were identified. 
All had raised serum ferritin but normal transferrin 
saturation. They were negative for hepatitis B and C and 
only one patient consumed excess alcohol. In all 4 cases 
ultrasonography revealed fatty liver. In two patients a 
liver biopsy was done and showed mild siderosis with 
an unusual distribution and macrovesicular steatosis. 
These data confirm the association between fatty liver, 
hyperferritinemia and increased hepatic iron, but do not 
clarify whether siderosis was related to steatosis rather 
than homozygosity for the H63D mutation. Patients 
with fatty liver may complicate the interpretation of 
data in population studies of the expression of H63D 
homozygosity. 
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Hereditary haemochromatosis (HH) is a common auto-
somal recessive disorder of  iron metabolism with an in-
cidence of  up to 1 in 200 and an estimated frequency of  
carriers of  1 in 10 among people of  Northern European 
descent[1-3]. The disease is characterized by enhanced gas-
trointestinal absorption of  iron to excessive accumulation 
in tissue, which may result in damage to liver and other 
target organs[4]. C282Y missense mutation in the HFE 
gene was found to be strongly related to the occurrence 
of  HH[2]. In a UK study, homozygosity for the C282Y 
mutation was found to account for 91 % of  HH[5]. A sec-
ond missense mutation in the HFE gene, H63D, is found 
in around 4% of  patients with HH, but its role in iron 
overload is still debated[2,6-8]. The H63D mutation is vari-
ably distributed worldwide. It is more prevalent than the 
C282Y mutation so that approximately one in five of  the 
European population are H63D heterozygotes[3,9]. Indi-
viduals who are compound heterozygous for C282Y and 
H63D can have iron overload in the range diagnostic of  
haemochromatosis, although the penetrance of  the geno-
type is low[2,10,11]. Similarly, homozygosity for H63D has 
been associated with iron overload, ranging from asympto-
matic subjects to patients with typical haemochromatosis. 
As with compound heterozygosity for C282Y/H63D, 
the penetrance is low and the phenotypic presentation of  
this genotype varied considerably[11,12]. The aim of  this 
study was to analyse the phenotypic expression of  H63D 
homozygotes identified through the genetic screening of  
patients referred to our Centre for HFE mutation analysis.
    366 consecutive blood samples, referred to the Centre 
for Hepatology at the Royal Free and University College 
Medical School (UCL), were analysed for HFE mutations. 
Mutation analysis was requested on the basis of  biochemi-
cal or clinical suspicion of  HH, family screening or known 
diagnosis of  haemochromatosis. Samples were obtained 
after informed written consent, where appropriate. C282Y 
and H63D mutations were detected by polymerase chain 
reaction (PCR) amplification of  total genomic DNA fol-
lowed by restriction digestion with RsaI and MboI en-
zymes respectively, as previously described[5].
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CASE REPORTS
Four males were found to be homozygous for the H63D 
mutation. Their main features are summarised in Table 1. 
Case 1 
English male patient aged 36 years with suspected iron 
overload indicated by a serum ferritin concentration of  
454 µg/L (reference range: 39-340). Serum iron, transfer-
rin saturation and total iron binding capacity (TIBC) were 
normal. He was referred because of  abnormal levels of  
liver enzymes and elevated serum ferritin found during 
investigation for dyspepsia. He consumed 8 g of  alcohol 
per week. He had a positive family history for obesity and 
maturity onset diabetes mellitus. There was no family his-
tory of  haemochromatosis. On examination he was well, 
overweight and mildly hypertensive (140/100). Abdominal 
examination was normal. Liver function tests showed: 
ALT 117 U/L, AST 46 U/L and γGT 50 U/L. Viral mark-
ers for hepatitis B and C were negative. Ultrasonography 
revealed a large liver, with diffuse hyperechogenicity, char-
acteristic of  fatty change. Since the liver enzymes and the 
ferritin remained persistently elevated, a liver biopsy was 
performed. It showed moderate macrovesicular steatosis 
(grade 2 on a scale of  0 to 3) with grade 1 siderosis (on a 
scale of  0 to 4)[13] in periportal hepatocytes and Kupffer 
cells, with evidence of  pericellular fibrosis of  zone 3 (stage 
1 of  steatohepatitis according to Brunt et al[14]). The sinu-
soidal cells had unusual granular siderosis (Figures 1A, 1B, 
1C). The hepatic iron concentration was increased being 
185 µg/100g dry weight (reference range: 35-136). The 
patient was seen every three months for 2 years to monitor 
transaminases and ferritin. On the basis of  the result of  
the liver biopsy, venesection therapy was started, together 
with dietary restrictions. Over a period of  two years, he 
was treated with seven phlebotomies and approximately 1.3 
g of  iron were removed. The serum ferritin concentration 
returned to normal at 95 µg/L as did liver function tests 
except for minimal elevation of  ALT at 45 U/L.
Case 2 
Male patient aged 35 years from Lebanon with mild abnor-
mality of  iron indices. In 1996 he had a routine check-up 
and was found to have abnormal ALT (175 U/L) and AST 
(69 U/L), together with a minimally elevated serum ferritin 
(350 µg/L). Serum iron, TIBC and transferrin saturation 
were normal, as were the other liver function tests. The 
family history was negative for haemochromatosis. The 
patient did not drink alcohol. Viral markers for hepatitis B 
and C were negative. Between 1989 and 1995 he had been 
a blood donor giving approximately 2 units (approximately 
450 mL each) of  blood every year. On examination he had 
a normal build with gynaecomastia. Blood pressure was 
normal. Abdominal examination showed a palpable liver 
Table 1 Clinical, biochemical and serological features of the 
four H63D homozygous patients
   Case 1  Case 2 Case 3 Case 4
Age (yr)                36              35           44         66
BMI (kg/m2)               30              24           32.5         31
Blood pressure (mmHg)          140/100      130/80     160/100    150/95
Alcohol intake (g/wk)                 8                0           60           0
Blood sugar (mmol/L)                 4.2               4.6            5.6           9.5
Total cholesterol (mmol/L)         4.1               4.3            5.5           6
Triglicerides (mmol/L)               1.6               1.5            3.6           2.9
AST (U/L)                46              69           44         15
ALT (U/L)                                  117            175         112         18
γGT (U/L)                  50              45           70         30
Ferritin (µg/L)             454            350         568       423
HCV/HBV serology            neg            neg         neg       neg
Legend: BMI=body mass index; wk=week; neg=negative. Normal ranges: 
BMI 18 - 25 kg/m2; blood pressure max < 120mmHg, min<80mmHg (see the 
seventh report of the Joint National Committee on high blood pressure, NIH 
publication no 03 - 5233, December 2003); blood sugar < 6mmol/L. 
Figure 1  Case 1 liver histology. A: Hematoxylin and eosin staining shows grade 
2 hepatic steatosis; B: Perls’ staining shows grade 1 hepatocyte siderosis with 
predominant periportal distribution; C: Higher power of Perls’ staining shows 
clustered Kupffer cell siderosis (right lower field) and also irregular large granular 
deposits in sinusoidal cells.
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Figure 2 Case 2 liver histology. A: Hematoxylin and eosin staining shows grade 
2 hepatic steatosis; B: Perls’ staining shows grade 2 hepatocyte siderosis with 
predominant periportal distribution; C: Higher power shows focal Kupffer cell 
siderosis and more granular irregular sinusoidal siderosis.
on deep inspiration (2 cm) but no other abnormalities. 
The alpha-1-antitrypsin level was 1.0 g/L (normal range 
1.2-2.6 g/L). Analysis showed him to have phenotype 
MZ. Ultrasound examination revealed a hyperechogenic 
liver compatible with hepatic steatosis. A liver biopsy was 
performed and showed moderate macrovesicular steato-
sis (grade 2) without fibrosis (stage 0 of  steatohepatitis[14]). 
There was grade 2 siderosis in periportal hepatocytes, 
and focal Kupffer cell iron. The sinusoidal cell iron had a 
granular pattern similar to that seen for case 1 (Figures 2A, 
2B, 2C). No cholestasis or alpha-1-antitrypsin staining was 
detected.
    The patient was seen every three months for 4 years to 
monitor transaminases and ferritin, which remained per-
sistently elevated.
 
Case 3
Irish male patient aged 44 years referred with possible 
iron overload indicated by a ferritin concentration of  568 
µg/L. Serum iron, transferrin saturation and TIBC were 
normal. He was referred to our clinic in November 1998 
to investigate raised levels of  liver transaminases: ALT was 
112 U/L, AST 44 U/L and γGT 70 U/L. The family his-
tory was positive for obesity and maturity onset diabetes 
mellitus and was negative for haemochromatosis. Physi-
cal examination showed a middle aged obese man (103 
kg/178 cm; Body Mass Index (BMI) =32.5 kg/m2). Blood 
pressure was elevated in the supine position (160/100) 
and the hypertension was treated with Tenif  one per day 
(atenolol 50 mg, nifedipine 20 mg) and Valsartan (80 mg/
day). The patient had also a history of  moderate alcohol 
abuse (alcohol intake: 60 g/week) and elevated triglyceride 
levels (3.61 mmol/L). Viral markers for hepatitis B and C 
were negative. Ultrasonography of  the abdomen revealed 
a liver of  normal size, but with echoreflectivity consistent 
with fatty liver. No liver biopsy was done. The patient was 
seen every three months for 2 years to monitor weight, 
transaminases and ferritin. He abstained from alcohol. 
Dietary therapy was started and the patient lost 6 kg in 
weight. No venesection was performed. During follow-up, 
liver function tests remained mildly abnormal with an ALT 
of  84 U/L. The other enzymes fell to normal levels and 
triglycerides fell to 1.73 mmol/L. Despite abstinence and 
losing weight, his ferritin remained elevated (482 µg/L). 
The possibility of  iron overload was raised and the patient 
was genotyped for mutations in the HFE gene and found 
to be homozygous for H63D. 
Case 4 
English male patient aged 66 years with an elevated serum 
ferritin concentration (423 µg/L) on a background of  type 
2 diabetes and peripheral neuropathy. Serum iron, transfer-
rin saturation and TIBC were normal. He was diagnosed as 
hypertensive in February 1988 and he is currently treated 
with Enalapril. He also had atrial fibrillation for which he 
has been treated with warfarin. He was treated for diabetes 
mellitus with gliclazide, metformin and acarbose. Physical 
examination showed no features of  chronic liver disease 
and no hepatomegaly. Liver function tests were normal. 
Viral markers for hepatitis B and C were negative. Abdom-
inal ultrasonography revealed an enlarged and fatty liver. 
Since his ferritin levels remained in the region of  400 µg/L, 
the patient was tested for mutations in the HFE gene and 
found to be homozygous for H63D mutation.
DisCussion
Four H63D homozygotes were identified by screening 366 
blood samples referred for genetic analysis in the HFE 
gene. All the four patients had high serum ferritin. It is 
noteworthy that in all the cases an abdominal ultrasonogra-
phy showed fatty liver. In the two cases where liver biopsy 
was done and histology showed not only mild siderosis 
of  hepatocytes, typical of  iron overload of  HFE-related 
haemochromatosis, but also siderosis of  sinusoidal cells, 
with a granular pattern that could be related to nonalco-
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holic steatohepatitis (NASH). Both patients had significant 
macrovesicular steatosis. One patient was treated with di-
etary restriction and venesection, after which liver function 
tests and serum ferritin concentration returned to normal. 
These findings suggest that hepatic steatosis, together with 
a biological effect of  the H63D mutation, could be re-
sponsible for the hepatic siderosis in these patients. Recent 
evidence suggests that H63D homozygosity could lead to 
iron overload with variable penetrance and phenotype[12]. 
However, an association with fatty liver has not been 
previously reported. Another study of  more than 10,000 
blood donors suggested an effect of  H63D homozygos-
ity on iron metabolism[15], although the mean serum iron 
indices for this genotype were within the normal range, 
possibly reflecting the fact that blood donors are in general 
healthy and young (mean age was 38 years for men and 
36 years for women). These findings have been reinforced 
experimentally by the demonstration that transgenic mice 
homozygous for the H63D mutation have elevated trans-
ferrin saturation and hepatic iron concentration compared 
to wild type mice[16].
    H63D homozygosity could thus contribute to iron 
overload but the phenotypic expression may be influenced 
by cofactors. Sex, age, diet and modifier genes are likely 
to influence penetrance of  the genotype. In this series all 
4 cases were male and this reflects the relative protection 
of  women from iron overload by menstruation and preg-
nancy. Furthermore, three of  the cases had one or more 
metabolic disorders which are part of  the insulin resist-
ance syndrome (IRS)[17]. Case 1 was overweight (BMI>25 
kg/m2) and mildly hypertensive, Case 3 was obese (BMI>30 
kg/m2) and had hypertriglyceridemia and hypertension 
requiring antihypertensive treatment. Case 4 was obese, 
he had type 2 diabetes mellitus requiring therapy, hyper-
trigliceridemia and hypertension under therapy.
    Although hyperferritinemia may be associated with he-
patic steatosis per se[18,19], in two patients presented here 
hepatic siderosis with an unusual histological pattern was 
present. Homozygosity for H63D may have played a role, 
but the unusual cellular pattern raises the possibility that 
in some cases of  hepatic steatosis there are other changes 
in cellular iron handling which result in iron accumulation. 
Alterations in cytokines and hence hepcidin may result in 
accumulation of  iron in sinusoidal cells[20,21]. A role for the 
mutations in the HFE gene in other diseases, however, has 
been suggested by their over-representation in subjects 
with NASH and with the dysmetabolic iron overload syn-
drome (DIOS) characterized by an association between 
iron overload and insulin resistance[22-24]. The molecular 
mechanism explaining these associations is not clear. He-
patic steatosis has been recognised as the first of  two “hits” 
in the pathogenesis of  NASH, since the presence of  oxi-
disable fat within the liver is enough to trigger lipid peroxi-
dation[25]. However, many patients with fatty liver do not 
progress to necroinflammation[26]. It has been suggested 
that the second hit for the development of  NASH may be 
oxidative stress, leading to necroinflammation[27]. Several 
potential second hits have been suggested. Iron even in 
relatively low concentrations could synergize with lipid 
overload and induction of  ethanol-inducible cytochrome 
P450 2E1 (CYP2E1) to increase oxidative stress in hepato-
cytes[28]. 
     If  iron leads to oxidative stress and to progression of  
non-alcoholic fatty liver to NASH, venesection therapy 
is theoretically beneficial, and this may have contributed 
to the normalisation of  serum ferritin concentration 
and improvement of  liver function tests in Case 1. In 
conclusion, our findings confirm a link between fatty liver 
and mild iron accumulation. Whether homozygosity for 
H63D contributed to the association is uncertain. Further 
studies of  iron regulatory proteins are needed in hepatic 
steatosis. 
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